Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study

被引：0
|
作者：
Hu, P. [1 ]
Xie, Q. [2 ]
Li, Y. [3 ,11 ]
Chen, X. [4 ,19 ]
Dou, X. [5 ]
Jiang, J. [6 ,20 ]
Shang, J. [7 ]
Zhang, W. [8 ]
Gong, G. [9 ]
Sun, Y. [10 ]
Li, Y. [3 ,11 ]
Liu, Y. [12 ]
Liu, G. [13 ]
Mao, D. [14 ]
Chi, X. [15 ]
Tang, H. [16 ]
Li, X. [17 ]
Xie, Y. [18 ]
Chen, X. [4 ,19 ]
Jiang, J. [6 ,20 ]
Zhao, P. [21 ]
Hou, J. [22 ]
Gao, Z. [23 ]
Fan, H. [24 ]
Ding, J. [25 ]
Ren, H. [1 ]
机构：
[1] Chongqing Med Univ, Infect Dis, Affiliated Hosp 2, Chongqing, Peoples R China
[2] Shanghai Jiao Tong Univ, Infect Dis, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[3] Harbin Med Univ, Affiliated Hosp 1, Harbin, Peoples R China
[4] Capital Med Univ, Int Med Dept, Beijing YouAn Hosp, Beijing, Peoples R China
[5] China Med Univ, Shengjing Hosp, Infect Dis, Shenyang, Peoples R China
[6] Guangxi Med Univ, Affiliated Hosp 1, Infect Dis, Nanning, Peoples R China
[7] Henan Prov Peoples Hosp, Infect Dis, Zhengzhou, Peoples R China
[8] Fudan Univ, Huashan Hosp, Infect Dis, Shanghai, Peoples R China
[9] Cent S Univ, Xiangya Hosp 2, Infect Dis, Changsha, Hunan, Peoples R China
[10] Fourth Mil Med Univ, Infect Dis, Tangdu Hosp, Xian, Peoples R China
[11] Ningxia Med Univ, Infect Dis, Gen Hosp, Yinchuan, Peoples R China
[12] Shenzhen Third Peoples Hosp, Liver Dis Dept, Shenzhen, Peoples R China
[13] Cent S Univ, Infect Dis, Xiangya Hosp, Changsha, Hunan, Peoples R China
[14] Guangxi Univ Chinese Med, Liver Dis Dept, Affiliated Hosp 1, Nanning, Peoples R China
[15] Guangdong Hosp Tradit Chinese Med, Liver Dis Dept, Guangzhou, Guangdong, Peoples R China
[16] Sichuan Univ, Infect Dis, West China Hosp, Chengdu, Peoples R China
[17] Sixth Peoples Hosp Hangzhou, Liver Dis Dept, Hangzhou, Zhejiang, Peoples R China
[18] Capital Med Univ, Beijing Ditan Hosp, Liver Dis Dept, Beijing, Peoples R China
[19] Guangdong Gen Hosp, Infect Dis, Guangzhou, Guangdong, Peoples R China
[20] Fujian Med Univ, Affiliated Hosp 1, Liver Dis Dept, Fuzhou, Peoples R China
[21] 302 Hosp PLA, Int Ctr Liver Dis Treatment, Beijing, Peoples R China
[22] Southern Med Univ, Nanfang Hosp, Infect Dis, Guangzhou, Guangdong, Peoples R China
[23] Sun Yat Sen Univ, Affiliated Hosp 3, Infect Dis, Guangzhou, Guangdong, Peoples R China
[24] Guangzhou Eighth Peoples Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China
[25] Ruian Peoples Hosp, Hepatol Unit, Ruian, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30842-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-175
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [41] The baseline combination of HBcrAg and HBsAg titers enhance treatment outcome and HBsAg loss predictions in HBeAg negative chronic hepatitis B patients treated with pegylated interferon alfa-2a or PegIFN plus Tenofovir-disoproxil-fumarate
    Martinot-Peignoux, Michelle
    Lapalus, Martine
    Boyer, Nathalie
    Castelnau, Corinne
    Giuily, Nathalie
    Pouteau, Michele
    Moucari, Rami
    Asselah, Tarik
    Marcellin, Patrick
    HEPATOLOGY, 2015, 62 : 1205A - 1205A
  • [42] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in a large, multinational trial of patients with chronic hepatitis B
    Fried, MW
    Liaw, YF
    Luo, KX
    Lau, GK
    Piratvisuth, T
    Cooksley, G
    Marcellin, P
    Thongsawat, S
    Mai, C
    Flisiak, R
    McCloud, P
    Why, D
    Pluck, N
    HEPATOLOGY, 2005, 42 (04) : 268A - 268A
  • [43] Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients
    Buster, Erik H. C. J.
    Flink, Hajo J.
    Simsek, Halis
    Heathcote, E. Jenny
    Sharmila, Sachithanandan
    Kitis, George E.
    Gerken, Guido
    Buti, Maria
    de Vries, Richard A.
    Verhey, Elke
    Hansen, Bettina E.
    Janssen, Harry L. A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 (10): : 2449 - 2457
  • [44] HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Drakoulis, C.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S286 - S287
  • [45] HBSAG LOSS WITH TENOFOVIR DISOPROXIL FUMARATE PLUS PEGINTERFERON ALFA-2A IN CHRONIC HEPATITIS B: LONG-TERM RESULTS OF A GLOBAL RANDOMIZED CONTROLLED TRIAL
    Ahn, S. -H.
    Marcellin, P.
    Ma, X.
    Caruntu, F.
    Tak, W. Y.
    Elkhashab, M.
    Chuang, W. -L.
    Tabak, F.
    Mehta, R.
    Petersen, J.
    Corsa, A.
    Martins, E. B.
    Yee, L. J.
    Dinh, P.
    Subramanian, G. Mani
    Buti, M.
    Gaeta, G.
    Papatheodoridis, G.
    Flisiak, R.
    Chan, H. L. Y.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S524 - S525
  • [46] HBsAg Loss with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2a (PEG) in Chronic Hepatitis B (CHB): Results of a Global Randomized Controlled Trial
    Marcellin, Patrick
    Ahn, Sang Hoon
    Ma, Xiaoli
    Caruntu, Florin A.
    Tak, Won Young
    Elkashab, Magdy
    Chuang, Wan-Long
    Tabak, Fehmi
    Mehta, Rajiv
    Petersen, Joerg
    Martins, Eduardo B.
    Dinh, Phillip
    Corsa, Amoreena C.
    Charuworn, Prista
    Subramanian, Mani
    McHutchison, John G.
    Buti, Maria
    Gaeta, Giovanni B.
    Papatheodoridis, George V.
    Flisiak, Robert
    Chan, Henry Lik-Yuen
    HEPATOLOGY, 2014, 60 : 294A - 295A
  • [47] Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis
    Lampertico, Pietro
    Brunetto, Maurizia R.
    Craxi, Antonio
    Gaeta, Giovanni B.
    Rizzetto, Mario
    Palmieri, Giulio
    Colombo, Massimo
    HEPATOLOGY, 2014, 60 (06) : 1285A - 1286A
  • [48] ADD-ON PEGINTERFERON ALFA-2A SIGNIFICANTLY REDUCES HBSAG LEVELS IN CHRONIC HEPATITIS B, HBEAG-NEGATIVE, GENOTYPE D PATIENTS FULLY SUPPRESSED ON NUCLEOT(S)IDE ANALOGUES TREATMENT: HERMES STUDY INTERIM ANALYSIS
    Lampertico, P.
    Brunetto, M. R.
    Craxi, A.
    Gaeta, G. B.
    Rizzetto, M.
    Palmieri, G.
    Colombo, M.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E28 - E28
  • [49] PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB) WITH A MAINTAINED VIROLOGICAL RESPONSE TO ENTECAVIR ACHIEVED HBSAG CLEARANCE WHEN SWITCHED TO PEGINTERFERON ALFA-2A THERAPY (THE OSST STUDY)
    Ning, Qin
    Han, Meifang
    Sun, Yongtao
    Jiang, Jia-ji
    Tan, Deming
    Hou, Jinlin
    Tang, Hong
    Sheng, Ji-Fang
    Jiang, Michael
    HEPATOLOGY, 2011, 54 : 1010A - 1011A
  • [50] A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS POST-TREATMENT TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Lampertico, P.
    Messinger, D.
    Cornberg, M.
    Brunetto, M.
    Petersen, J.
    Kennedy, P.
    Asselah, T.
    Rothe, V.
    Caputo, A.
    Bakalos, G.
    Pavlovic, V.
    Papatheodoridis, G. V.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S599 - S600
12345